SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA), one of the key drivers of the most aggressive cancers, today announced presentations at two upcoming conferences in October:
- Precision Lung Cancer: World R&D Summit: Jason Christiansen, Chief Technology Officer of Boundless Bio, will give a presentation titled “Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification.” The presentation will take place at 3:00 p.m. EDT on Wednesday, Oct. 23, 2019 in Boston, Massachusetts.
- 2019 BIO Investor Forum: Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will give a company overview on Wednesday, Oct. 23, 2019 at 2:00 p.m. PDT in San Francisco, California.
Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells’ chromosomes and can make many copies of themselves. The ecDNA can be rapidly replicated within the cell, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division. Cells have the ability to upregulate or downregulate the ecDNA and resulting oncogenes to ensure survival under selective pressures, including chemotherapy or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment evasion. ecDNA are rarely seen in healthy cells, but are found in a large number of all solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers—specifically, those characterized by high copy number amplification of oncogenes.
About Boundless Bio
Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com.